Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sagimet Biosciences Inc.

NASDAQ: SGMT · Life Sciences · 5 alerts · CIK 1400118

Share price
$10.13Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sagimet Biosciences Inc. filings on SEC EDGAR ↗

7:49 AM ET 8-K
Financial Results

Sagimet Biosciences Financial Results

Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.

“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”

David Happel, Chief Executive Officer
7:31 AM ET 10-Q
Financial Results

Sagimet Biosciences Q3 2026 Results: Net Loss of $19.1M, Loss Widens

Sagimet Biosciences Inc. reported a significant increase in total assets to $282.1 million as of September 30, 2026, up from $116.5 million at the end of 2025, primarily driven by growth in cash and marketable securities. The company is advancing its lead drug candidate, denifanstat, through clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Current liabilities also increased to $38.0 million, including a $27.5 million liability for proceeds received for equity not yet issued.

Key figure
Net loss $19.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.